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Background: Patients with chronic severe asthma (CSA) have a crippling disease and current available treatments
are not satisfactory. Thus, management of CSA remains a major unmet need. Although the evidence from existing
randomized controlled trials fails to support a definite role for immunomodulatory drugs in these patients due to
major methodologic drawbacks, findings with low-dose methotrexate (MTX) are encouraging. However, larger and
well-designed clinical trials are required to establish the beneficial role of MTX in CSA, and for the detection of the
key characteristics of those who are going to respond to this drug.
Methods/design: Patients will be recruited from the accessible asthmatic patients lists of tertiary referral centers.
All patients will meet the stringent diagnostic criteria for CSA, including the requirement for the regular use of
Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention Step 5 medications
(oral prednisone and/or omalizumab). The experimental design of the proposed study will take the form of a
double-blind parallel-randomized placebo-controlled trial consisting of a total of eight visits, including run-in and
run-out periods. Patients will be randomly allocated to receive either MTX or a matched placebo once a week as an
add-on therapy to their existing medication after run-in. Physiological, laboratory and clinical assessments will be
measured regularly throughout the study and compared with baseline assessments.
Discussion: We expect that MTX will reduce Step 5 medications dosage in patients with CSA without compromising the
overall disease control. Improvement in several indicators of asthma severity and control will be also investigated.
Trial registration: ClinicalTrials.gov Identifier: NCT02124226 (assigned 25 April 2014).
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Asthma is a multifactorial disease characterized by various
phenotypes and heterogeneous pathological mechanisms,
which affects 5 to 20% of the population in Europe, North
America and Australia with a rising prevalence, particu-
larly amongst pediatric and elderly populations [1-3].* Correspondence: polosa@unict.it
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unless otherwise stated.Over the last 50 years, there has been an escalation in
knowledge about the cells and mediators involved in the
disease’s pathogenesis. The identification of the Th2 cell as
the key ‘orchestrator’ of the allergic response, culminating
in the interleukin (IL)-4 and IL-13 dependent generation
of immunoglobulin E (IgE) by dedicated follicular B cells
and plasma cells, has represented a central finding for
many years [4]. However, alternative T-cell subtypes (for
example, Th1 cells, regulatory T-cells and Th17 cells) are
now being taken into consideration [5], and mixed endo-
types are currently being proposed [6].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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surprising that many asthma patients continue to have
uncontrolled disease that requires either improved adher-
ence to medications or high intensity treatment [7-9].
Patients with severe unremitting disease have the greatest
impairment of their quality of life and account for a dispro-
portionate use of healthcare resources through hospital ad-
missions, unscheduled doctor’s visits and use of emergency
services [10,11]. The accurate prevalence of such cases is
unknown, but may fluctuate around 5 to 8% of the total
asthma population, depending on the definition [12,13].
Asthmatic patients with this aggressive phenotype
respond poorly to standard treatments and acceptable
control of the symptoms can only be achieved by taking
regular systemic corticosteroids [14,15]. Although the low-
est possible dose should be prescribed, this subgroup of
patients often needs high doses of oral corticosteroids
(OCS) (prednisone ≥25 mg/day) in order to attain an
adequate asthma control and exhibits a deterioration as
soon as the dose of corticosteroids is tapered. Further-
more, some of these patients may respond poorly to oral
prednisone because of an intrinsic form of insensitivity to
corticosteroids [16]. Hence, reasonable control of their
asthma can then only still be achieved at the cost of
significant adverse effects.
The past years have witnessed the successful introduc-
tion of a new drug entity for the severe asthma phenotype:
the monoclonal anti-IgE antibody, omalizumab. Nonethe-
less, omalizumab is currently approved for add-on use
only in the small subset of allergic severe asthma patients
[17,18]. Therefore, for non-allergic asthma patients with
severe chronic disease, a combination of OCS with a var-
iety of oral and nebulized bronchodilators, in addition to
high-dose inhaled corticosteroids and beta2 agonists, is
the only recommended strategy by current international
asthma guidelines. Collectively, omalizumab and systemic
steroids represent the most intensive level of treatment
schedule for asthma and constitute the so-called treat-
ment category ‘Step 5’ in the Global Initiative for Asthma
(GINA) Global Strategy for Asthma Management and
Prevention guidelines [18].
It is clear, that the current therapeutic arsenal is unsat-
isfactory and management of asthmatic patients with
severe refractory disease remains a major unmet need.
Despite the development of a plethora of new biologic
therapies targeting specific inflammatory cells or recep-
tors of inflammatory mediators relevant to asthma, these
highly specific tools can achieve only limited improve-
ment in patients with severe refractory disease and are
very expensive [19,20].
Clinical experience with immunomodulatory agents for
the treatment of patients with chronic inflammatory
rheumatic diseases suggests that these therapies are
very effective and at low dose appear to be safe forlong-term use [21]. The notion that the efficacy of these
agents is also resulting from their well-known steroid-
sparing activity can be exploited in other inflammatory
diseases, including chronic severe asthma. Therefore, a
more widespread use of current immunomodulatory
therapies for chronic severe asthma has been proposed
[22,23]. Specifically, weekly low-dose methotrexate (MTX)
has been shown to substantially decrease daily prednisone
dose in steroid-dependent asthmatic patients in random-
ized controlled trials [24].
Large and well-designed controlled studies are now
required to establish the role of MTX in chronic severe
asthma patients and to detect the key characteristics of
those who are going to respond to this drug. With this in
mind, we designed a prospective randomized controlled
trial in well-characterized patients with chronic severe
asthma to evaluate the efficacy of an add-on weekly low
dose of MTX in reducing the total dose of Step 5 medica-
tions (OCS and/or omalizumab) without deterioration in
respiratory symptoms and airway function. We will also
monitor low-dose MTX adverse events and tolerability.
Methods/Design
Participants
Patients with chronic severe asthma will be recruited from
the accessible asthmatic patients lists of tertiary referral
centers to ensure the recruitment of 102 patients. All
patients will meet the current GINA diagnostic criteria for
chronic severe asthma, which includes the requirement for
the use of GINA Step 5 medications (oral prednisone and/
or omalizumab) [18]. Full details of antiasthma treatment
use including high-dose inhaled corticosteroids, leukotriene
modifiers, theophylline, long acting beta-agonists, long act-
ing muscarinic antagonists, will be recorded at enrolment.
Inclusion criteria
Study inclusion criteria are as follows:
1. patients with a diagnosis of chronic severe asthma
taking GINA Step 5 medications (regular OCS and/
or omalizumab for a minimum of six months);
2. failure in weaning patients completely from Step 5
medications during run-in;
3. male and female individuals aged 18 to 75 years;
4. patients must be able to provide consent.
Exclusion criteria
Study exclusion criteria are as follows:
1. use of immunomodulatory therapies in the
preceding three months;
2. recent or current history of alcoholism;
3. high liver enzyme levels (greater than 2.5 times the
upper limit of the normal range);
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5. acute illness within 15 days of study medication
administration;
6. leucopenia (below 3.0 × 109/L) and/or
thrombocytopenia (below 100 × 109/L);
7. pregnancy or planning to become pregnant;
8. evidence of pulmonary fibrosis or chronic liver
disease.
Patients thought to have uncontrolled asthma as a conse-
quence of co-existent conditions (such as gastro-esophageal
reflux or chronic rhinosinusitis) will not be excluded.
Participants will be allowed to adjust controller and reliever
medication use as necessary throughout the study and
these details will be reported in a clinical diary. The phys-
ician in charge will explain the objectives of the study and
obtain informed consent from patients invited for the
enrolment visit. Patient organizations will also locally
assist the enrolment procedure by informing their patients
about the study. We anticipate to complete enrolment
within six months. The study protocol has been approved
by the Ethics Committee of the Azienda Ospedaliera
Universitaria Policlinico - V Emanuele di Catania (record
number: 682; 28-01-2014) in accordance with the Helsinki
Declaration. The coordinating centre has centralized eth-
ical approval. Ethical approval from each participating
centre will be obtained prior to patients’ recruitment.Trial design
The design is a double-blind parallel-randomized placebo-
controlled trial. The placebo and the active drug will be
provided by the study sponsor; the company will not be
involved in the study design, data collection, analysis or
interpretation of the data. According to sample size esti-
mation, a total of 102 patients will enter the study (see
Sample size estimates section below).
A schematic diagram of the study design is presented in
Figure 1. In brief, patients will be invited for an enrolment
visit (visit 0) to check for eligibility and for baseline mea-
surements. This visit will be followed by a run-in period
during which optimization of OCS doses prior to ran-
domization will be achieved. Steroid doses will be progres-
sively tapered (5 mg/day of prednisone every week)
until a decrease of >10% in the forced expiratory vol-
ume in 1 second (FEV1) is observed. Steroid dose will
then be increased to the previous level and the tapering
strategy will be repeated once again to establish the
minimum dose needed to stabilize FEV1. Patients on
omalizumab will be also subjected to a dose-reduction
strategy; doses will be progressively reduced by 50%
every six weeks until a decrease of >10% in the FEV1 is
observed. If necessary, the omalizumab dose will then
be increased to the previous level.At the end of the run-in period, patients will attend an
entry visit (visit one) to confirm eligibility and to repeat
baseline measurements. At this time, patients will be
randomly allocated to receive either MTX (starting dose
of 7.5 mg/week plus folic acid the day after) or matched
placebo (once a week for three weeks) as an add-on
therapy to their existing medication. Randomization will
be undertaken by a professional contract research organ-
ization (CRO). At the subsequent visit (visit two) three
weeks later, study treatment dosage will be increased
(thus, for those on MTX, the maintenance dose will be
10 mg/week plus folic acid the day after). The mainten-
ance dose will be administered for a total of 27 weeks.
Selection of the dose and duration of treatment are
chosen from seminal clinical trials of MTX in patients
with active rheumatoid arthritis [21]. Progressive step-
wise dose-reduction in GINA Step 5 medications will
begin three weeks later, at visit three. If possible, dose
reductions will be attempted every six weeks for OCS
and every 12 weeks for omalizumab, according to the
strategy illustrated in Figure 1. Physiological, laboratory
and clinical assessments will be repeated regularly at
six-week intervals (visits four to seven).
At the end of the active treatment period (visit seven),
patients will enter a run-out period, during which modifi-
cations of the patients’ asthma symptoms and medications
will be carefully documented. At the end of the run-out
period, patients will attend a final visit (visit eight) to
repeat physiological, laboratory and clinical assessments.
At visits five, seven and eight a blood sample will be taken
for estimation of intracellular levels of MTX polygluta-
mates (MTXPGs) in blood cells for possible clinical corre-
lations and prediction of MTX responders. MTXPGs assay
will be carried out centrally.
The proposed timetable for conducting and completing
the study is summarized below:
1. Consensus agreement on diagnostic criteria,
standardization of procedures, investigators training
sessions and ethical approvals: three to four months;
2. Recruitment phase and patients inclusion: six to
eight months;
3. Run-in phase and verification of inclusion criteria:
three to four months;
4. Randomization followed by treatment phase: seven
months;
5. Run-out phase: 12 months;
6. Data collection, data check and statistical analysis:
three to four months;
7. Final report: one month.
Study intervention
Patients randomly allocated to receive MTX will be
given a subcutaneous injection once a week (initially
Figure 1 A schematic diagram of the study design. MTX: Methotrexate. PROs: Patient Reported Outcomes. US: Ultrasound. MTXPG: Methotrexate
Polyglutamate. AEs: Adverse Events.
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maintenance dose of 10 mg/week for a total of 27 weeks)
as add-on therapy to their existing medication. The
placebo is matched to have an identical appearance to
the active drug. A prescription of 5 mg folic acid per
week with MTX therapy is recommended to reduce
side effects; folic acid will be taken by all participants
(both MTX and placebo-treated). Treatment dose and
duration are chosen from seminal clinical trials of
MTX in patients with active rheumatoid arthritis [21];
MTX has a sound safety profile according to the evi-
dence from these trials and the longstanding experience
with its use. If lab results are suggestive of MTX tox-
icity, treatment will be suspended and the patient will
be withdrawn from the study, with re-evaluation after
three to four weeks. Regarding less severe side effects,
such as stomatitis and/or abdominal discomfort, these
respond well to symptomatic treatment. The active
drug and matched placebo will be provided by the
study sponsor.Study outcomes
Primary outcome measures
According to the most recent revision of the international
asthma guidelines [18], the combination of OCS and/or
omalizumab in addition to high-dose inhaled corticoste-
roids and bronchodilators to achieve control (falling under
the highest category known as Step 5 medications) is
recommended for patients with chronic severe asthma.
Therefore, the primary measured outcome of efficacy for
this study will be: at least 50% reduction in total dosage of
Step 5 medications (systemic steroids and/or omalizumab)
without compromising the overall disease control. Dose
reductions from baseline can be calculated from the
clinical diary. Reductions in the total dose of Step 5 medi-
cations by MTX will reduce the risk of serious adverse
effects and will lead to considerable cost savings.
Secondary outcome measures
All major clinical trials on patients with chronic severe
asthma have substantially demonstrated that FEV1 is not
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[25-28]. For this reason, we considered it inadequate to
accept FEV1 as a primary endpoint in this study pro-
posal. Alternatively, for some of these clinical trials,
patient-reported outcomes such as the Asthma Quality
of Life Questionnaire (AQLQ) and the Asthma Control
Questionnaire (ACQ) have proved to be acceptable clin-
ical endpoints [29,30]. Therefore, the secondary measured
outcomes of efficacy for this study will be:
1. no significant deterioration in lung function (FEV1);
2. a clinically significant change (at least 0.5 point) in
the AQLQ score [29];
3. a clinically significant change (at least 0.5 point) in
the ACQ score [30].
The number of severe asthma exacerbations from the
previous follow-up visit (a severe asthma exacerbation is
defined as an increase in respiratory symptoms requiring
a short course of oral or parenteral corticosteroids) will
be also recorded throughout the study and used as add-
itional secondary measured outcomes of efficacy. Dose
reductions in inhalational therapy from baseline will also
be calculated from the clinical diary. Incidence of hep-
atotoxicity will be used as safety outcome.
Methotrexate polyglutamates assay
Samples of heparinized peripheral whole blood (5 mL) ob-
tained from participants receiving MTX will be centrifuged
at a low speed for 10 minutes to pellet the red blood cells
(RBCs). RBCs are then resuspended in an equal volume of
normal saline (Baxter Deerfield, IL, USA), mixed by gentle
inversion, and subjected to a second low-speed centrifuga-
tion. After discarding the supernatant, the packed RBCs are
divided into two aliquots and stored at −70°C until analysis.
To increase specificity and minimize interference with
coeluting substances, the ion-pair reverse-phase chroma-
tography (IPRPC) method is used to identify methotrexate
glutamate (MTXGlu) in human RBCs to profile mono- and
polyglutamated folates. Briefly, sample preparation consists
of a simple protein-precipitation step, followed by solid-
phase extraction. The reconstituted sample is separated by
IPRPC with N, N-dimethylhexylamine as an ion-pairing
reagent (Sigma-Aldrich Corp., St. Louis, MO, USA), result-
ing in an elution order proportional to the MTX polygluta-
mation status. Detection of each MTXGlu is carried out
using a micromass Ultima triple quadropole mass spec-
trometer (Agilent Technologies, CA, USA), operating in
positive ion mode. The lower limit of detection is found to
be in the 0.1 to 0.5 nM range for each MTXGlu.
Blinding and randomization
In this parallel two-arm double-blind, placebo-controlled
study, patients with chronic severe asthma taking GINAStep 5 medications will be randomized to either MTX or
matched placebo. The randomization sequence will be
generated by an ad-hoc statistical program. A statistician
will run the program to generate a random list on the
basis of the number of patients and the treatment blocks.
Once printed, the randomization list will be sealed in a
close enveloped and archived. Masking of the active drug
will be professionally carried out by a professional CRO;
the personnel involved in administering interventions and
assessing outcomes at the participating centers will not be
aware of treatment assignment.
Information retrieval
Patients’ data will be collected by means of an electronic
case report form (eCRF). The eCRF is built up on the
basis of the study protocol and is divided into visits
sections on the basis of the study design. Prior to its im-
plementation into the study, eCRF will be approved for
adherence with current legislation for privacy and data
protection. Data collected with eCRFs will be automatic-
ally feeding a central study database. An eCRF training
session about data entry procedures will be provided to
all those involved. Potential data entry errors that could
be made by the medical staff at the site will be reduced
by data verification activities by the CRO in charge, and
resolved either through monitoring visits or through
ad-hoc teleconferences.
Organizational aspects and study feasibility
Recruiting centers will be selected on the basis of their
expertise in the management of chronic severe asthma,
availability of a significant number of these patients’
phenotype and documented experience in clinical trials.
Working definitions for this study have been already dis-
cussed, reviewed and agreed, together with the analysis
of potential recruitment impediments. Moreover, focus-
ing on sound and clinically relevant primary outcome
measures it is likely to improve the scientific yield and
optimize overall recruitment. A competitive recruitment
strategy will be employed to ensure optimal patients are
recruited in a timely manner.
Coordination and management will be provided by a
professional CRO. Before the commencing the study,
investigators will be invited to a kick-off meeting during
which consensus agreement on diagnostic criteria will
be reached, the study protocol will be explained in detail
and a specific training session about the standardization
of all study procedures, the treatment scheme and good
clinical practices (GCP) will be offered. The CRO will be
in charge of training sessions and the monitoring of GCP
principles throughout the study. The CRO will monitor
the quality of the data and the progress of the study, with
an eye towards identifying delays early and working
with investigators to develop rapid solutions. A list of
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ment in case of the study underperforming. MTX-PG
assay will be carried out centrally. Statistical analyses of
the data and realistic delivery of the results is guaranteed
by the involvement of a dedicated team of biostatisticians.
Sample size estimates and statistical analysis
A total of 102 patients will enter this two-treatment
parallel-design study. The sample size is calculated to
give 90% power to reject a two-sided test of the null
hypothesis that there is no treatment difference between
MTX and placebo, with respect to the primary outcome
variable. The probability is that the study will detect a
treatment difference at a two sided 5.0% significance
level if the true difference between the treatments is 4.56
units. This is based on the assumption that the standard
deviation of the response variable is 5.1 [24]. The requisite
for stratification by daily (high or low) prednisone dose
at randomization and a dropout estimate of 20% of the
participants have been also taken into account.
Our statistical hypothesis is that the study will be able
to show the superiority of MTX treatment versus placebo
so that it significantly reduces the individual’s Step 5
medications needs of at least 50% with respect to base-
line. All analyses will be performed according to the
intention-to-treat principle. Baseline characteristics mea-
sured on a nominal or ordinal scale will be compared by
the chi-square test or analysis of variance, respectively. In
the primary analysis, the proportions of patients in the
two study groups who successfully reached the primary
outcome will be compared with the use of Fisher’s exact
test. Subjects will be stratified on the basis of their daily
(high or low) steroid dose at the run-in period, and differ-
ences between the high-dose and low-dose strata, with
regard to the outcome, will be compared by a logistic
regression analysis model. An interim analysis will be
performed by the O’Brien-Fleming method when 75% of
subjects are included into the study to reveal possible sig-
nificant differences between treatment groups. The daily
prednisone dose will be compared by repeated-measures
analysis of variance. The number of patients withdrawn
from therapy because of adverse reactions or treatment
failure will be compared between study groups by Fisher’s
exact test. Secondary efficacy variables will be analyzed by
the chi-square test and analysis of variance.
Discussion
Current available medications for chronic severe asthma
are not satisfactory and improvement in the management
of chronic severe asthma is much needed. It is surprising
that the initial encouraging experience of using no- ster-
oidal immunological modifiers for severe asthma has been
neglected. Most likely, significant drawbacks in method-
ology and study design, and disproportionate concernsabout immunomodulators’ toxicity have contributed to this.
Small sample size, vague disease definition, heterogeneous
patient populations, unsatisfactory follow-up period, lack of
adequate run-in for stabilization of patients’ steroid require-
ments, poorly defined response criteria for steroid tapering,
short treatment duration and under-dosing have all con-
tributed to the poor quality of earlier trials [22,23].
However, among the collection of immunologic modi-
fiers, low-dose MTX has a well-established safety record
and long-term observational studies have also shown its
efficacy and safety in asthma patients [31-33]. In particular,
two prospective open-labelled extension studies reported
that more than half of the patients treated with MTX for
up to 28 months discontinued OCS completely [34,35].
Furthermore, one double-blind randomized placebo-
controlled study (of 46 steroid-dependent asthmatic
patients) observed a decrease in corticosteroids in more
than half of the patients in the MTX group, showing
the drug’s efficacy as a steroid-sparing agent and with
good tolerance [24]. The effect of MTX in increasing
T-cell’s susceptibility may at least partly account for its
OCS-sparing effect in severe asthma [36]. Although no
firm conclusion can be reached based on the limited
evidence, it is clear that low-dose MTX can be a useful
therapeutic option for chronic severe asthma [37]. Large
and well-designed controlled studies are now needed to
establish a positive role for MTX in chronic severe
asthma, and to identify the key characteristics of those
who are going to respond to this drug.
The study presented here has been designed to address
most of the methodologic problems encountered in earlier
clinical trials investigating efficacy and safety of MTX in
chronic severe asthma patients. First of all, chronic severe
asthma patients will be characterized with great care prior
to inclusion; phenotypization of these participants will
have to conform to current GINA diagnostic criteria for
chronic severe asthma [18], and to the recently established
criteria for chronic refractory asthma by the Unbiased Bio-
markers for the Prediction of Respiratory Disease Outcome
(U-BIOPRED) Consortium [38]. In particular, the inclusion
of a run-in period designed to establish patients’ lowest
possible GINA Step 5 medications (systemic steroids and/
or omalizumab) requirements is very important to confirm
the stability and validity of their sub-phenotype.
Secondly, this study will have enough power to endorse
the role of add-on MTX as a valuable drug in patients
with chronic severe asthma. In estimating the sample size,
we had to consider that most clinical trials on patients
with chronic severe asthma have shown the futility of
using FEV1 as a realistic primary endpoint for this disease
phenotype [25-28]. Moreover, patient-reported outcomes
such as the AQLQ and ACQ have proved to be acceptable
clinical endpoints in mild-to-moderate asthma, but very
little is known about their validation in patients with
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ical indicators in chronic severe asthma will be possible in
the context of our study in a well-characterized cohort of
patients with chronic severe asthma. For these reasons, the
sample size has been calculated on the basis of a sound and
clinically relevant endpoint; no less than a 50% reduction in
dosage of Step 5 medications from baseline was considered
as a key primary outcome of efficacy for patients with
chronic severe asthma. Particular attention has been paid
to a clear working definition for the response criteria during
steroid and/or omalizumab tapering.
Thirdly, treatment duration and MTX dosing will be
sufficient enough to determine if patients with chronic
severe asthma will derive beneficial clinical effects (or
cumulative adverse events) from regular MTX use. Lastly,
this study includes a 12-month duration run-out period,
during which modifications of the patients’ asthma symp-
toms and medications will be carefully documented. This
important extension of the study design has been included
to crosscheck any potential valuable contribution of
low-dose MTX in responders.
Hopefully this study will show substantial reductions
in the total dose of Step 5 medications by MTX, thus
reducing the risk of serious adverse effects of systemic
corticosteroids, and contributing to considerable cost
savings. A significant reduction in the total dose of oral
steroids will reduce the risk of serious adverse effects
such as osteoporosis, diabetes, hypertension and gastro-
intestinal bleeding. This will lead not only to considerable
savings in the form of less frequent monitoring of bone
mineral density, fasting glucose and blood pressure, but
also through discontinuation of biphosphonates for bone
protection, and of proton pump inhibitors for gastrointes-
tinal bleeding prevention. It is worth noting that because
of the growing number of patients with chronic severe
asthma using omalizumab to improve their disease con-
trol, we will end up recruiting not only patients taking
regular OCS, but also patients on omalizumab. Therefore,
this study has the potential of addressing for the first
time the role of low-dose MTX in reducing the total
dose of omalizumab without compromising overall disease
control. In consideration of the high acquisition cost of
omalizumab a significant reduction in the total dose of
omalizumab by the much cheaper MTX may lead to
substantial savings.
The present study will be the first multicenter ran-
domized controlled trial investigating the role of add-on
low-dose MTX in patients with well-phenotyped chronic
severe asthma. Hopefully findings from this study will
advance current knowledge and recommendations about
the characterization, evaluation and treatment of chronic
severe asthma [38,39]. In particular, we expect to confirm
that MTX may be considered for inclusion in the current
therapeutic arsenal for chronic severe asthma.Trial status
We expect to start recruiting patients into the study in
September 2015.
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